On December 21, 2025, Moleculin Biotech, Inc. amended its Series E, F, and G warrants to lower the exercise price to $3.90 per share. Following efforts to meet Nasdaq's listing requirements, the company's stockholders' equity increased to over $10 million as of now, following a reported deficit of $26.9 million as of September 30, 2025.